此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Osimertinib联合Capivasertib治疗先前接受过一线Osimertinib治疗且伴有PIK3CA/AKT1/PTEN基因改变的NSCLC (Precision)

2026年11月18日 更新者:Shanxi Province Cancer Hospital

奥希替尼联合卡匹瓦替尼在经一线奥希替尼单药或联合化疗后进展的、携带PIK3CA/AKT1/PTEN基因改变的EGFR突变晚期非小细胞肺癌(NSCLC)患者中的安全性和有效性:一项首次人体、Ib/Ⅱa期研究(PRECISION)

The goal of this clinical trial is to learn if Osimertinib plus Capivasertib works to treat EGFRm advanced non-small cell lung cancer (NSCLC) in participants with PIK3CA/AKT1/PTEN alterations after progression on first-line Osimertinib (monotherapy or plus chemotherapy).

The main questions it aims to answer are:

Part A:

  • Number of Dose-limiting toxicities (DLTs)
  • Adverse events (AEs)/serious adverse events (SAEs) (graded by CTCAE Version 5.0)
  • Recommended combined dose (RCD)

Part B:Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria.

Participants will:

Part A:Take Capivasertib twice daily from day 1 to 4 of a 7-day cycle, Osimertinib will be given orally QD(once daily) at 80 mg throughout the study treatment period.

Part B: Take Osimertinib (80mg QD, continuously) and Capivasertib(RCD,orally BID from day1-day 4 in 7-day cycle , 4 days on /3 days off) till disease progression (PD) or unacceptable toxicity.

研究概览

详细说明

This is a two-stage study, consisting of Phase Ib dose-escalation, Phase IIa dose expansion. Safety will be intensively monitored in Part A. If RCD (Recommended combined dose) was not reached in Part A, Part B (dose expansion phase) would not be initiated. If RCD was reached in Part A, eligible patients in Part B will be enrolled and receive Osimertinib (80mg QD, continuously) plus Capivasertib (RCD, orally BID from day1-day 4 in 7-day cycle , 4 days on /3 days off) till disease progression (PD) or unacceptable toxicity, with the aim to further evaluate the safety, tolerability and efficacy in terms of ORR, DCR, DOR, PFS and OS.

All participants (18 and above) will undergo screening (Day -28 to -1), treatment period (starting from Day 1) and post-intervention follow-up period (end of treatment visit, 30-day safety follow-up and survival follow-up).

Dose escalation(Part A) will follow the classic "3+3" schema. The DLT observation period is 28 days post first dose of study treatment. Dose escalation will occur only after DLT observation period is completed for a minimum of 3 participants, relevant data has been reviewed within the Safety Review Committee (SRC), and the SRC approves dose escalation.

研究类型

介入性

注册 (估计的)

53

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国
        • Cancer Hospital Chinese Academy of Medical Sciences
        • 接触:
    • Shanxi
      • Taiyuan、Shanxi、中国
        • Shanxi Cancer Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion criteria

Informed consent

  1. Provision of signed and dated, written informed consent form (ICF) prior to any mandatory and non-mandatory study-specific procedures, sampling and analyses

    Age

  2. Male or female age ≥18 years at the time of signing the ICF.

    Type of participant and disease characteristics

  3. Histologically or cytologically confirmed non-squamous locally advanced or metastatic NSCLC which is not amenable to curative therapy.

  4. Documented EGFR sensitive mutations (exon19 deletion, L858R mutation) prior to the first-line EGFR-TKI therapy.

  5. Documented radiologic progression on first-line treatment with Osimertinib monotherapy or Osimertinib plus chemotherapy:

    • Participants treated with Osimertinib in the adjuvant setting can be included if progression occurred < 6 months after last dose.
    • Participants must be immunotherapy (i.e., programmed cell death protein 1 [PD-1] inhibitor, programmed cell death protein 1 ligand 1 [PD-L1] inhibitor, Cytotoxic T-lymphocyte associated protein 4 inhibitor) naïve in the metastatic setting.
    • Prior immunotherapy in the neoadjuvant or adjuvant setting is acceptable providing treatment was completed more than 6 months before metastatic/recurrent disease was diagnosed.
  6. Mandatory provision of the required number of FFPE tumour tissue samples for PIK3CA mutations and/or AKT1 mutations and/or PTEN loss-of-function (LOF) mutations testing, which fulfils the following requirements:

    • Obtained following progression on previous Osimertinib monotherapy or Osimertinib plus chemotherapy as first-line treatment.
    • Specimen to meet the requirements defined in the Central Laboratory Manual and Diagnostic Testing Manual.
    • Have PIK3CA and/or AKT1 and/or PTEN alterations as determined by NGS testing by a sponsor designated central laboratory on tumour specimen collected following progression on prior Osimertinib treatment.
  7. At least one lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with CT or MRI, which is suitable for accurate repeated measurements. If only one measurable lesion exists, it is acceptable to be used if baseline tumour assessment scans are done at least 14 days after the screening tumour specimen collection is performed.

  8. Adequate bone marrow reserve and organ function as follows:

    • Absolute neutrophils count (ANC) ≥1.5x109/L.
    • Platelets count ≥100x109/L.
    • Haemoglobin (Hb) ≥90g/L.
    • Total bilirubin ≤1.5 times upper limit of normal (ULN) or ≤3 times ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases.
    • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5ULN (or ≤5 ULN in the presence of liver metastases).
    • Creatinine clearance (CrCl) ≥50 ml/min (measured by 24hr urine output or calculated by Cockcroft and Gault equation).
  9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  10. Patients with hepatitis B virus (HBV) are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of hepatitis C virus (HCV) co-infection or history of HCV co-infection
    • Demonstrated absence of human immunodeficiency virus (HIV) infection
    • Participants with active HBV infection are eligible if they are:
    • Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to <100 IU/mL and transaminase levels are below ULN.
    • Participants with a resolved or chronic HBV infection are eligible if they are:
    • Negative for HBsAg and positive for hepatitis B core antibody [anti-HBc IgG or total anti-HBc Ab]. In addition, patients should be referred to a local hepatologist and treated as per local guidelines.

    or

    • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below <100 IU/mL or below the detectable limit of locally available test kit (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment.

    Patients with HIV are only eligible for inclusion if they meet all the following criteria:

    • Demonstrated absence of HBV/ HCV co-infection
    • Undetectable viral RNA load for 6 months
    • CD4+ count of >350 cells/µL
    • No history of AIDS-defining opportunistic infection within the past 12 months

    Stable for at least 4 weeks on the same anti-HIV medications.

  11. Ability to swallow and retain oral medications.

  12. Willingness and ability to comply with study and follow-up procedures. Reproduction

  13. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

    • Post-menopausal defined as aged 50 years or more and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.
    • Women under 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

    Further information in Appendix C (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods).

  14. Male participants must be willing to use barrier contraception.

Exclusion criteria

Medical conditions

  1. Patients harbouring concurrent actionable driver mutations with locally approved targeted therapies (e.g., MET amplification) will be excluded.

  2. Past medical history of ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

  3. Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    • Fasting glucose ≥7.0 mmol/L (126 mg/dL) or 2 hours after glucose solution intake, blood glucose ≥11.1 mmol/L (200 mg/dL).
    • HbA1c ≥8.0% (63.9 mmol/mol) at screening. Note: for any patient with evidence of impaired glucose control or insulin resistance refer to the Capivasertib Toxicity Management Guidelines.
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection (e.g. patients receiving treatment for infection) including hepatitis C and human immunodeficiency virus (HIV), or active uncontrolled hepatitis B virus (HBV) infection, or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice) .

    • Screening for chronic conditions is not required.

  5. Spinal cord compression, leptomeningeal metastasis, or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.

  6. Any of the following cardiac criteria:

    • Mean resting corrected QTc >470 msec, obtained from triplicate electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value.

    • History of QT prolongation associated with other medications that required discontinuation of that medication.

    • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block and second-degree heart block.

    • Medical history significant for arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (Common Terminology Criteria for Adverse Events [CTCAE] Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted to enter the study based on the Investigator judgement with cardiologist consultation recommended.

    • Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities, heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes:

      • Patients with hypokalaemia|* ≥ CTCAE Grade 2 at screening are excluded.
      • - Hypomagnesaemia and hypocalcaemia are acceptable at screening if ≤ CTCAE Grade 1. Values > Grade 1 for magnesium or calcium should be corrected to ≤ Grade 1 prior to first dose, with documentation of the correction attempt.
    • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) Grade 2.

  7. History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥2 years before the first dose of investigational product (IP) and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.

  8. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment except for alopecia and grade 2 prior platinum-therapy related neuropathy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the Investigator may be included (e.g., hearing loss).

  9. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of IP.

  10. Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.

    Prior/concomitant therapy

  11. Prior or current treatment with a third-generation EGFR-TKI other than Osimertinib.

  12. Prior or current treatment with any PI3K/AKT pathway inhibitors, including but not limited to: Capivasertib or other AKT inhibitors, PI3K inhibitors, or agents targeting key nodes in this pathway (e.g., PTEN-modulating therapies).

  13. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer.

  14. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to starting study intervention or has not recovered from side effects of such therapy.

  15. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. Procedures such as placement of vascular access, biopsy via mediastinoscopy or biopsy via video assisted thoracoscopic surgery (VATS) are permitted.

  16. Systemic therapy: Prior exposure to any anti-cancer agents other than those specified in the protocol (e.g. hormonal therapy such as luteinizing hormone releasing hormone [LHRH] agonists) without appropriate washout period before enrolment, for example, enrolment within 3 half-lives of a small molecule anti-cancer agent, or within 4 weeks for any antibody-based anticancer agents.

  17. Participants who are currently taking strong CYP3A4 inducers and cannot discontinue them at least 3 weeks before the first study dose must be excluded (Appendix B). This is because strong CYP3A4 inducers can decrease the exposure of osimertinib.Any concomitant medication that may interfere with Osimertinib safety and efficacy based on the prescribing information of Osimertinib and local clinical guidelines.

    Prior/concurrent clinical study experience

  18. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

    Other exclusions

  19. History of hypersensitivity to active or inactive excipients of Capivasertib or Osimertinib or drugs with a similar chemical structure or class.

  20. Women who are currently pregnant (confirmed with positive pregnancy test) or breast-feeding or planning to become pregnant.

  21. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Capivasertib 320/400 mg in combination with Osimertinib 80mg

Capivasertib 320/400 mg (twice daily from day 1 to 4 of a 7-day cycle ),Osimertinib 80 mg( once daily continuously),28 days per cycle

Capivasertib 320/400 mg(twice daily from day 1 to 4 of a 7-day cycle ),Osimertinib 80 mg(once daily continuously),28 days per cycle

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
A部分 不良事件(AEs)/严重不良事件(SAEs)(根据CTCAE 5.0版本分级)
大体时间:自签署知情同意书起至44个月
自签署知情同意书起至44个月
Part A Number of Dose-limiting toxicities (DLTs)
大体时间:28 days post first dose of study treatment

A DLT is defined as any toxicity related to study drug and not attributable to the disease or disease-related processes under investigation, which occurs from the first dose of study treatment (Day 1, Cycle 0) up to the last day of Cycle 1 (28 days after start of dosing)

28 days post first dose of study treatment
Part A Recommended combined dose (RCD)
大体时间:From first dose of study treatment up to 12 months

The RCD is defined as the optimal dose combination of study drugs, established based on integrated assessment of safety and relevant available data from dose escalation phase

From first dose of study treatment up to 12 months
Part B Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
大体时间:5 months post first dose of study treatment

ORR is defined as the percentage of participants who have at least one confirmed response of CR or PR prior to any evidence of progression (as determined by investigator at local site per RECIST 1.1)

5 months post first dose of study treatment

次要结果测量

结果测量
措施说明
大体时间
B部分 药物不良反应(ADR)
大体时间:从签署知情同意书起至28个月内
从签署知情同意书起至28个月内
Part A Confirmed ORR assessed by the Investigator per RECIST 1.1 criteria
大体时间:5 months post first dose of study treatment

Confirmed ORR as defined in Primary Outcome Measure 4

5 months post first dose of study treatment
Part B Progression-free survival(PFS)
大体时间:From first dose of study treatment up to 27 months

PFS is defined as the time from initiation of study treatment to the date of objective disease progression or death (by any cause in the absence of progression), which occurs first, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression

From first dose of study treatment up to 27 months
Part B Duration of response(DoR )
大体时间:From 1 months post first dose of study treatment up to 27 months

DOR will be defined as the time from the date of first documented response (which is subsequently confirmed), until date of documented progression or death in the absence of disease progression

From 1 months post first dose of study treatment up to 27 months
Part B Disease control rate(DCR)
大体时间:From 2 months post first dose of study treatment up to 27 months

Disease control rate is defined as the proportion of patients with a best overall response of confirmed CR, confirmed PR, or SD

From 2 months post first dose of study treatment up to 27 months
Part B Overall survival(OS)
大体时间:From first dose of study treatment up to 27 months

Overall survival is defined as the time from the date of initiation of study treatment until death due to any cause

From first dose of study treatment up to 27 months
Part B AE/SAE
大体时间:From the time of signature of informed consent form up to 28 months

Number of participants with adverse events (AEs) according to CTCAE 5.0

From the time of signature of informed consent form up to 28 months
Part B Adverse events of special interest(AESI)
大体时间:From the time of signature of informed consent form up to 28 months

AESIs are events of scientific and medical interest specific to the further understanding of the safety profile of Capivasertib plus Osimertinib when given in combination and require close monitoring and rapid communication by the investigators to AstraZeneca. An AESI can be serious or nonserious

From the time of signature of informed consent form up to 28 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月8日

初级完成 (估计的)

2029年5月15日

研究完成 (估计的)

2029年7月31日

研究注册日期

首次提交

2026年2月25日

首先提交符合 QC 标准的

2026年3月17日

首次发布 (实际的)

2026年3月20日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月18日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅